Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week High Following Analyst Upgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price hit a new 52-week high during mid-day trading on Wednesday after Truist Financial raised their price target on the stock from $798.00 to $820.00. Truist Financial currently has a buy rating on the stock. Regeneron Pharmaceuticals traded as high as $807.83 and last traded at $799.4370, with a volume of 204887 shares trading hands. The stock had previously closed at $776.54.

Several other equities analysts also recently issued reports on the company. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. UBS Group boosted their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Citigroup increased their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Finally, HSBC began coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $791.05.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,431 shares of company stock worth $5,733,521 in the last three months. Company insiders own 7.02% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from Underperform to Buy and lifted its price target to $860, citing improving fundamentals and 2026 catalysts, a clear bullish catalyst for the stock. Regeneron Pharmaceuticals upgraded by Bank of America
• Positive Sentiment: Truist raised its price target to $820 and reiterated a Buy, adding incremental upside and supporting analyst-driven demand. Truist raises price target
• Positive Sentiment: Aggregated analyst coverage is shifting more positive (multiple upgrade pieces and a roundup of 21 analyst views), which can drive buy-side interest and shorten-term momentum. 21 analysts assess Regeneron
• Neutral Sentiment: Unusual options activity has been reported, indicating increased speculative positioning and hedging that can amplify intraday moves but is ambiguous for longer-term direction. Unusual options activity
• Neutral Sentiment: Coverage pieces note falling short interest and renewed bullish cases; lower short interest reduces short-squeeze potential but supports steadier upside if fundamentals hold. Analyst upgrades and short-interest drop
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 on Jan. 7, which can be viewed by some investors as a signal to take profits. Director share sale disclosed

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Marino Stram & Associates LLC increased its position in shares of Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares in the last quarter. CoreCap Advisors LLC grew its stake in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 20 shares during the period. Strait & Sound Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 21 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 21 shares in the last quarter. Finally, MAI Capital Management raised its position in Regeneron Pharmaceuticals by 2.1% during the third quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock worth $578,000 after acquiring an additional 21 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.4%

The company’s fifty day simple moving average is $735.23 and its 200-day simple moving average is $626.08. The firm has a market capitalization of $84.19 billion, a PE ratio of 19.18, a P/E/G ratio of 2.42 and a beta of 0.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $12.46 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.